Paul Sekhri was President and CEO of Genesis from 2019-2022 where he remains a Board Member and Senior Advisor to the Chairman. Prior to eGenesis, he was President and CEO of Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease. Prior to joining Lycera, Mr. Sekhri was Senior Vice President, Integrated Care at Sanofi, where he led the creation of innovative solutions and business models to meet patient needs. Previously, he served as Group Executive Vice President, Global Business Development and Chief Strategy Officer at Teva Pharmaceutical Industries Ltd. Prior to this, Mr. Sekhri was Operating Partner and Head, Biotech Ops Group at TPG Biotech. Previously, Mr. Sekhri founded and was President and Chief Executive Officer of Cerimon Pharmaceuticals, focused on autoimmune diseases and pain management, and prior to that, was President and Chief Business Officer of Ariad Pharmaceuticals. Earlier in his career, he held senior positions at Novartis Pharma AG, including as Senior Vice President and Head, Global Search and Evaluation and M&A. Mr. Sekhri received his BS degree from the University of Maryland, and completed post-graduate studies at the University of Maryland School of Medicine.
Mr. Sekhri has been a Director on more than 30 private, public company, and non-profit Boards, and is currently a Director at Ipsen, S.A., Compugen, Pharming N.V., Veeva Systems, Longboard, Spring DIscovery, and eGenesis. Additionally he is on the Board of Directors of The Metropolitan Opera, The English Concert in America, and was a member of the Board of Trustees of Carnegie Hall. Most recently he was named Chairman of the Board of the Knights Ensemble.
